Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
90 Results for "
HBV replication
" in MedChemExpress (MCE) Product Catalog:
Products (90)
90 Results for "HBV replication" in MCE Product Catalog:
Cat. No.: HY-177667A
Tomligisiran sodium is a siRNA in JNJ-3989 (JNJ-73763989). JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.
Cat. No.: HY-116607
CAS No.: 246872-58-2
BAY38-7690 is a non-nucleoside inhibitor that inhibits HBV replication. BAY38-7690 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY38-7690 against HBV in stably transfected HepG2.2.15 cells is 0.15 μM .
Cat. No.: HY-117999
CAS No.: 247037-81-6
BAY39-5493 is a non-nucleoside inhibitor that inhibits HBV replication. BAY39-5493 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY39-5493 against HBV in stably transfected HepG2.2.15 cells is 0.03 μM .
Cat. No.: HY-147255A
CAS No.: 2137847-77-7
Synonyms: (S)-ZM-H1505R
(S)-Canocapavir is the isomer of Canocapavir (HY-147255A). Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished
production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection .
production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection .
Cat. No.: HY-170605
CAS No.: 1362113-74-3
BA-AZT1 is the inhibitor for HBV polymerase and sodium taurocholate cotransporting polypeptide (NTCP). BA-AZT1 inhibits the secretion of viral capsid protein HBsAg and HBeAg with IC50 of 0.65 µM and 13.42 µM, inhibits the HBV DNA replication with an IC50 of 0.70 µM .
Cat. No.: HY-B0017S
CAS No.: 1134182-00-5
Synonyms: Epavudine-d4; L-Thymidine-d4; NV 02B-d4
Cat. No.: HY-162579
CAS No.: 3036114-68-5
Target:
Research Areas:
TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC50 value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents .
Synonyms: Epavudine (Standard); L-Thymidine (Standard); NV 02B (Standard)
Target:
Research Areas:
Telbivudine (Standard) is the analytical standard of Telbivudine. This product is intended for research and analytical applications. Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication .
Cat. No.: HY-173278
Target:
Research Areas:
AIC263282 is a potent Hepatitis B Virus (HBV) capsid assembly modulator with an EC50 of 3.8 nM. AIC263282 shows an IC50 of 61 nM for hERG. AIC263282 exhibits activity against viral replication and hepatitis B surface antigen (HBsAG) on primary human hepatocytes .
Cat. No.: HY-114956
CAS No.: 300669-68-5
AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection .
Cat. No.: HY-119702
CAS No.: 1835652-66-8
YZ51 is a derivative of Osalmid (HY-B2116) with stronger ribonucleotide reductase (RR) inhibitory activity and HBV replication inhibition ability than Osalmid. The IC50 of YZ51 against recombinant RR activity is 0.6 μM, and the IC50 against HepG2.2.15 cell RR activity is 23.7 μM .
Cat. No.: HY-W105601
CAS No.: 161599-46-8
Synonyms: 2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine
Target:
Research Areas:
5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine (2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine) is an antiviral compound that inhibits HBV reverse transcriptase activity. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine shows potential to control HBV replication in vitro. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine, as a nucleoside analog, may provide a new option for the suppression of chronic hepatitis B .
Cat. No.: HY-113308AS2
Cat. No.: HY-113308S
CAS No.: 1265681-64-8
Cat. No.: HY-183260
CAS No.: 3049354-73-3
Target:
Research Areas:
HBV-IN-57 is an orally active HBV inhibitor with pan-genotypic efficacy against HBV genotypes B/C. HBV-IN-57 inhibits HBV DNA replication and HBV capsid assembly. HBV-IN-57 can be used for the research of chronic hepatitis B .
Cat. No.: HY-180524
CAS No.: 3014372-17-6
CAB7-3 is an orally active HBV capsid assembly modulator (CAM). CAB7-3 exhibits an exceptional antiviral efficacy reducing HBV DNA with an EC50 = 70 nM, CC50 = 32.3 μM in HepDES19 cells. CAB7-3 exhibits significant anti-HBV activity in HBV-integrated HepDES19 (EC50 = 70 nM), HepAD38 (EC50 = 1 nM) and HBV-infected HLCZ01 cells (EC50 = 2 nM), respectively. CAB7-3 effectively reduces Hepatic HBV core protein levels and suppresses viral replication in vivo. CAB7-3 demonstrates a favorable drug-like and safety profile. CAB7-3 can be used for Hepatitis B Virus (HBV) research .
Cat. No.: HY-184358
CAS No.: 321941-76-8
CLEC5A-IN-1 is an inhibitor that binds to CLEC5A, with a Kd value of 277 nM. CLEC5A-IN-1 inhibits HBV replication. CLEC5A-IN-1 induces the production of IFNα and IFNβ. CLEC5A-IN-1 reduces serum HBsAg and HBV DNA levels, as well as hepatic HBcAg levels, in HBV-infected animals. CLEC5A-IN-1 increases the positive rate and levels of serum HBsAb in HBV-infected animals. CLEC5A-IN-1 can be used for the research of hepatitis B .
Cat. No.: HY-173121
KR019 is a potent HBV capsid assembly modulator, exhibits potent antiviral activity in HBV-replicating cells. KR019 binds to the hydrophobic pocket at the core protein dimer-dimer interface, misdirecting capsid assembly into genome-free capsids and thereby inhibiting viral replication .
Cat. No.: HY-179393
HBV-IN-54 is a selective and orally active HBV inhibitor. HBV-IN-54 exhibits anti-HBV activity in both HepAD38 cells (EC50 = 0.020 μM, CC50 > 100 μM) and HLCZ01 cells (EC50 = 0.024 μM, CC50 > 100 μM). HBV-IN-54 inhibits viral replication in vivo. HBV-IN-54 displays favorable physicochemical properties and high plasma stability. HBV-IN-54 can be used for research on Hepatitis B (HBV) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
